# Mettler-Toledo International share price today (Mettler-Toledo International Inc., MTD)

> Mettler-Toledo International Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. MTD · Healthcare · Diagnostics & Research · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/mtd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from the last 12 quarters
- Price: $1,698 (+19.9% in a year)
- P/E: 38.2× (higher than 82% of the last 4.6 years)
- Revenue (Jun 2026): $1.0 B (+4.5% on a year ago)
- Profit (Jun 2026): $233 M (+15.1% on a year ago)
- Operating margin: 31.2% (+3.8 points on a year ago)
- ROE: −3,677%, FY25
- ROIC: 42.3%, against a 10.3% cost of capital: +32.0 points

The main question: results are strong, and the P/E is higher than 82% of its own history. ## What is the Mettler-Toledo International share price today? Mettler-Toledo International Inc.'s share price was $1,698 at the close on 3 November 2026. It has been stalling near its high for 8 weeks. That is 26.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $1,032 and $1,698, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 15 weeks in a row. Over the last 10 years the share price moved +355% while the S&P 500 moved +255%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Mettler-Toledo International pay? Mettler-Toledo International Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Mettler-Toledo International on? Mettler-Toledo International is on one of our US lists: S&P 500 companies. [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)

## Is Mettler-Toledo International profitable? Mettler-Toledo International Inc. earned $233 M of net profit in the Jun 2026 quarter, +15.1% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY25 profit was $869 M. Over 4 years profit has grown 3.1% a year on average. That is 22.7% of the quarter's revenue. The same quarter a year earlier earned $202 M. For the full year, FY25 profit was $869 M (+0.7% on the year before). Why profit moved: revenue changed +4.5% on a year earlier and the margin moved +3.8 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +8.7% and revenue +6.9%. Profit and revenue are moving at about the same pace. ## How much revenue does Mettler-Toledo International make, and is it growing? Mettler-Toledo International Inc. reported $1.0 B of revenue in the Jun 2026 quarter, +4.5% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 4 years it has grown 2.0% a year on average. The last full year, FY25, came in at $4.0 B. The last four reported quarters add to $4.1 B. Recent pace: the last four quarters grew +6.9% on average, against 2.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +6.9%, against +5.0% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +9.1%, against +7.4% a year (stabilising). ## How much of every $100 of sales does Mettler-Toledo International keep? Mettler-Toledo International Inc.'s operating margin was 31.2% in the Jun 2026 quarter, 3.8 percentage points higher than the same quarter a year ago. Across 5 years it has been between 27.1% and 29.3%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +3.8 percentage points on the year while gross margin changed +4.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Mettler-Toledo International's profit turning into cash? Over the last 3 years, 115% of Mettler-Toledo International Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $956 M of operating cash against $869 M of profit. After $107 M of spending on assets, $849 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Mettler-Toledo International's cash go? Mettler-Toledo International Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $316 M on assets over the last 3 years. Averaged over those years that is 2.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $316 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Mettler-Toledo International's P/E ratio, and how does it compare with its own history? Mettler-Toledo International Inc.'s P/E is 38.2×, near the high end of its own history: higher than 82% of past readings. Its usual P/E (the middle reading) is 33.5×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +3.9% while the price moved +19.9%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +18.1% a year; about +4.2% a year came from earnings growth and about +13.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Mettler-Toledo International business getting better or worse? Mettler-Toledo International Inc.'s business is getting better. Profit growth hit its low 8 quarters ago at −11.6% and has recovered to +9.1%, with ROCE steady at 49.6%. This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## How much does Mettler-Toledo International earn on its capital? Mettler-Toledo International Inc. earned a ROE of −3,677% in FY25. Its return on capital used (ROIC) is 32.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 21.6% net margin and 1.08× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 21.6% net margin × 1.08× asset turnover × −157.08× leverage (assets divided by equity) ≈ −3,664.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 42.3% − 10.3% = +32.0 percentage points. The 10.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 42.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 40.9%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Mettler-Toledo International have too much debt? Mettler-Toledo International Inc. has total debt of $2.1 B against shareholder equity of $12.8 M as of Jun 2026, so its debt is 166.68× its equity. Year by year, that ratio went from 10.51 in FY21 to −95.84 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Mettler-Toledo International shareholding pattern? 3.3% of Mettler-Toledo International Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 2.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Mettler-Toledo International from balance-sheet trouble? For Mettler-Toledo International Inc., the Z-score is 10.29. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 10.29 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Mettler-Toledo International rank in its industry? 55.9 out of 100, rank 8 of 30 in Diagnostics & Research, with 81% of the evidence available. Mettler-Toledo International Inc. scores 55.9 out of 100 against the 30 companies it is compared with in Diagnostics & Research, ranking 8. A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. The four parts add up to the total exactly: 17 + 21 + 6.8 + 11.1 = 55.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Mettler-Toledo International compared with? Mettler-Toledo International ranks 8 of 30 Diagnostics & Research companies on the 4-Factor Sector Score, with 55.9 out of 100. 1. [CareDx, Inc.](https://www.sectoralpha.in/us/stocks/cdna) CDNA · leader · Evidence leans up · 64% evidence 62.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 33.9% · Profit 93.1% · Operating margin change 12.6 points · 62% evidence Capital efficiency 7.2/25 · ROCE -0.4% · Operating margin 0.2% · 76% evidence Valuation 10.6/20 · P/E 13.3× · PEG n/a · 15% evidence Relative strength 19.9/20 · Lead over its industry 110.8% · Lead over S&P 500 166.5% · 1 year 466.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.1 + 7.2 + 10.6 + 19.9 = 62.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Agilent Technologies, Inc.](https://www.sectoralpha.in/us/stocks/a) A · leader · Evidence leans up · 85% evidence 62.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 8.6% · Profit 18% · Operating margin change 2.9 points · 95% evidence Capital efficiency 18.4/25 · ROCE 15.4% · Operating margin 25.6% · 76% evidence Valuation 11.1/20 · P/E 27.1× · PEG 1.41 · 65% evidence Relative strength 11.7/20 · Lead over its industry -8.9% · Lead over S&P 500 21.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.8 + 18.4 + 11.1 + 11.7 = 62 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Medpace Holdings, Inc.](https://www.sectoralpha.in/us/stocks/medp) MEDP · leader · Evidence leans up · 85% evidence 61.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.1/35 · Revenue 20.3% · Profit 19.4% · Operating margin change 1.6 points · 95% evidence Capital efficiency 21.3/25 · ROCE 75.3% · Operating margin 23.1% · 76% evidence Valuation 12.2/20 · P/E 33.6× · PEG 1.29 · 65% evidence Relative strength 8.7/20 · Lead over its industry -11.9% · Lead over S&P 500 17.3% · 1 year 12.6% · 100% evidence · 11 of 12 weeks ahead Exact sum: 19.1 + 21.3 + 12.2 + 8.7 = 61.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Revvity, Inc.](https://www.sectoralpha.in/us/stocks/rvty) RVTY · leader · Too little evidence to rank firmly · 58% evidence 60.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue n/a · Profit n/a · Operating margin change 3.3 points · 45% evidence Capital efficiency 12.8/25 · ROCE 4.3% · Operating margin 17.1% · 76% evidence Valuation 8.8/20 · P/E 53.4× · PEG n/a · 15% evidence Relative strength 18.2/20 · Lead over its industry 7% · Lead over S&P 500 41.6% · 1 year 80.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 12.8 + 8.8 + 18.2 = 60.2 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [IDEXX Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/idxx) IDXX · turning · Evidence leans up · 81% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.1/35 · Revenue 12.8% · Profit 15.5% · Operating margin change 1.4 points · 83% evidence Capital efficiency 21.3/25 · ROCE 68.1% · Operating margin 35% · 76% evidence Valuation 7.1/20 · P/E 36.4× · PEG 1.97 · 65% evidence Relative strength 8.0/20 · Lead over its industry -21.5% · Lead over S&P 500 6.4% · 1 year -5.1% · 100% evidence · 1 of 12 weeks ahead Exact sum: 23.1 + 21.3 + 7.1 + 8 = 59.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Labcorp Holdings Inc.](https://www.sectoralpha.in/us/stocks/lh) LH · leader · Evidence leans up · 81% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.3/35 · Revenue 6.4% · Profit 31.2% · Operating margin change 0.9 points · 83% evidence Capital efficiency 13.4/25 · ROCE 9.9% · Operating margin 12.2% · 76% evidence Valuation 15.2/20 · P/E 22.9× · PEG 0.69 · 65% evidence Relative strength 8.9/20 · Lead over its industry -11.1% · Lead over S&P 500 19.1% · 1 year 40% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.3 + 13.4 + 15.2 + 8.9 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [GRAIL, Inc.](https://www.sectoralpha.in/us/stocks/gral) GRAL · leader · Evidence leans up · 61% evidence 56.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.9/35 · Revenue 23% · Profit n/a · Operating margin change 36.1 points · 62% evidence Capital efficiency 3.9/25 · ROCE -19.3% · Operating margin -332% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 19.4/20 · Lead over its industry 25.5% · Lead over S&P 500 63.9% · 1 year 75.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.9 + 3.9 + 10 + 19.4 = 56.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. Mettler-Toledo International Inc. this page MTD · leader · Evidence leans up · 81% evidence 55.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.0/35 · Revenue 6.9% · Profit 9% · Operating margin change 3.8 points · 83% evidence Capital efficiency 21.0/25 · ROCE 47.8% · Operating margin 31.2% · 76% evidence Valuation 6.8/20 · P/E 28.5× · PEG 2.27 · 65% evidence Relative strength 11.1/20 · Lead over its industry -11% · Lead over S&P 500 19.2% · 1 year 18% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17 + 21 + 6.8 + 11.1 = 55.9 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 9. [Natera, Inc.](https://www.sectoralpha.in/us/stocks/ntra) NTRA · leader · Evidence leans up · 64% evidence 54.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 37.8% · Profit n/a · Operating margin change 9.9 points · 62% evidence Capital efficiency 5.3/25 · ROCE -13.5% · Operating margin -10.3% · 76% evidence Valuation 11.4/20 · P/E -152.2× · PEG n/a · 15% evidence Relative strength 13.7/20 · Lead over its industry 9% · Lead over S&P 500 42.8% · 1 year 94.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.1 + 5.3 + 11.4 + 13.7 = 54.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Charles River Laboratories International, Inc.](https://www.sectoralpha.in/us/stocks/crl) CRL · leader · Evidence leans up · 64% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.6/35 · Revenue -0.7% · Profit n/a · Operating margin change -1.6 points · 62% evidence Capital efficiency 12.0/25 · ROCE 7.9% · Operating margin 15.1% · 76% evidence Valuation 11.3/20 · P/E -87.6× · PEG n/a · 15% evidence Relative strength 18.1/20 · Lead over its industry 17.8% · Lead over S&P 500 54.6% · 1 year 109.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11.6 + 12 + 11.3 + 18.1 = 53 · What this means: Relative strength against the index is 54.6%, and revenue and profit growth are weak. 11. [Quest Diagnostics Incorporated](https://www.sectoralpha.in/us/stocks/dgx) DGX · leader · Evidence leans up · 85% evidence 52.7 out of 100 Growth Capital Valuation Relative
12. [Adaptive Biotechnologies Corporation](https://www.sectoralpha.in/us/stocks/adpt) ADPT · leader · Evidence leans up · 64% evidence 52.1 out of 100 Growth Capital Valuation Relative
13. [Sotera Health Company](https://www.sectoralpha.in/us/stocks/shc) SHC · quiet · Evidence leans up · 71% evidence 51.3 out of 100 Growth Capital Valuation Relative
14. [IQVIA Holdings Inc.](https://www.sectoralpha.in/us/stocks/iqv) IQV · leader · Evidence leans up · 81% evidence 50.2 out of 100 Growth Capital Valuation Relative
15. [BillionToOne, Inc.](https://www.sectoralpha.in/us/stocks/blln) BLLN · turning · Too little evidence to rank firmly · 58% evidence 49.0 out of 100 Growth Capital Valuation Relative
16. [Danaher Corporation](https://www.sectoralpha.in/us/stocks/dhr) DHR · breaking out · Evidence leans down · 85% evidence 48.6 out of 100 Growth Capital Valuation Relative
17. [Illumina, Inc.](https://www.sectoralpha.in/us/stocks/ilmn) ILMN · leader · Evidence leans down · 71% evidence 48.4 out of 100 Growth Capital Valuation Relative
18. [OPKO Health, Inc.](https://www.sectoralpha.in/us/stocks/opk) OPK · turning · Evidence leans down · 64% evidence 48.2 out of 100 Growth Capital Valuation Relative
19. [Guardant Health, Inc.](https://www.sectoralpha.in/us/stocks/gh) GH · turning · Evidence leans down · 61% evidence 48.2 out of 100 Growth Capital Valuation Relative
20. [Veracyte, Inc.](https://www.sectoralpha.in/us/stocks/vcyt) VCYT · turning · Evidence leans down · 64% evidence 47.5 out of 100 Growth Capital Valuation Relative
21. [NeoGenomics, Inc.](https://www.sectoralpha.in/us/stocks/neo) NEO · losing its lead · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
22. [Twist Bioscience Corporation](https://www.sectoralpha.in/us/stocks/twst) TWST · leader · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
23. [Qiagen N.V.](https://www.sectoralpha.in/us/stocks/qgen) QGEN · breaking out · Evidence leans down · 81% evidence 45.0 out of 100 Growth Capital Valuation Relative
24. [Thermo Fisher Scientific Inc.](https://www.sectoralpha.in/us/stocks/tmo) TMO · leader · Evidence leans down · 85% evidence 44.8 out of 100 Growth Capital Valuation Relative
25. [RadNet, Inc.](https://www.sectoralpha.in/us/stocks/rdnt) RDNT · breaking out · Evidence leans down · 64% evidence 41.9 out of 100 Growth Capital Valuation Relative
26. [Waters Corporation](https://www.sectoralpha.in/us/stocks/wat) WAT · leader · Too little evidence to rank firmly · 58% evidence 39.2 out of 100 Growth Capital Valuation Relative
27. [ICON Public Limited Company](https://www.sectoralpha.in/us/stocks/iclr) ICLR · turning · Evidence leans down · 81% evidence 38.4 out of 100 Growth Capital Valuation Relative
28. [Castle Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/cstl) CSTL · breaking out · Evidence leans down · 64% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [Personalis, Inc.](https://www.sectoralpha.in/us/stocks/psnl) PSNL · turning · Most evidence points down · 61% evidence 33.1 out of 100 Growth Capital Valuation Relative
30. [GeneDx Holdings Corp.](https://www.sectoralpha.in/us/stocks/wgs) WGS · quiet · Most evidence points down · 71% evidence 24.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Diagnostics & Research](https://www.sectoralpha.in/us/sectors/diagnostics-research), all 30 compared on one page. ## Which companies are close to Mettler-Toledo International in size? Mettler-Toledo International is the 9th largest of 34 Diagnostics & Research companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Waters Corporation, IQVIA Holdings Inc. and Illumina, Inc. Just below it: Labcorp Holdings Inc., Quest Diagnostics Incorporated and Guardant Health, Inc. ### Diagnostics & Research companies close in size

1. [Waters Corporation](https://www.sectoralpha.in/us/stocks/wat) $45.2 billion
2. [IQVIA Holdings Inc.](https://www.sectoralpha.in/us/stocks/iqv) $43.3 billion
3. [Illumina, Inc.](https://www.sectoralpha.in/us/stocks/ilmn) $36 billion
4. Mettler-Toledo International Inc. $34 billion
5. [Labcorp Holdings Inc.](https://www.sectoralpha.in/us/stocks/lh) $28.7 billion
6. [Quest Diagnostics Incorporated](https://www.sectoralpha.in/us/stocks/dgx) $27.2 billion
7. [Guardant Health, Inc.](https://www.sectoralpha.in/us/stocks/gh) $23.5 billion

[All 34 Diagnostics & Research companies, largest first](https://www.sectoralpha.in/us/sectors/diagnostics-research#all-companies)

### Companies close in size in other industries

1. [Interactive Brokers Group, Inc.](https://www.sectoralpha.in/us/stocks/ibkr) $33.9 billion · Capital Markets
2. [Ecopetrol S.A.](https://www.sectoralpha.in/us/stocks/ec) $33.6 billion · Oil & Gas Integrated
3. Mettler-Toledo International Inc. $33.6 billion
4. [Nutrien Ltd.](https://www.sectoralpha.in/us/stocks/ntr) $33.5 billion · Agricultural Inputs
5. [Genmab A/S](https://www.sectoralpha.in/us/stocks/gmab) $33.1 billion · Biotechnology

## What else do people ask about Mettler-Toledo International? ### What is Mettler-Toledo International's stock price today? Mettler-Toledo International Inc.'s stock price is $1,698, +19.9% over the past year. The whole company is worth $34.0 B on the market. It is at its highest price of the past 52 weeks (range $1,032 to $1,698), 26.8% above its 200-day average. The price has been stalling near its high for 8 weeks (as of 3 November 2026). ### What were Mettler-Toledo International's latest quarterly results? Mettler-Toledo International Inc. reported revenue of $1.0 B and net profit of $233 M for the Jun 2026 quarter. Revenue rose 4.5% and profit rose 15.1% compared with a year earlier. Earnings per share were $11.55. The operating margin was 31.2%, 3.8 percentage points higher than a year earlier (as of 3 November 2026). ### What is Mettler-Toledo International's market cap? Mettler-Toledo International Inc.'s market capitalisation is $34.0 B at a stock price of $1,698. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Mettler-Toledo International performing? Mettler-Toledo International Inc.'s share price has been stalling near its high for 8 weeks. In its latest quarter, revenue rose 4.5% and profit rose 15.1% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 15 weeks running (as of 3 November 2026). ### Will Mettler-Toledo International's stock price go up? This page does not forecast Mettler-Toledo International Inc.'s stock price. What it shows instead: the stock price is $1,698, and it has been stalling near its high for 8 weeks. Its P/E of 38.2× is higher than 82% of its own last 5 years (as of 3 November 2026). ### Where is Mettler-Toledo International in its business cycle? Mettler-Toledo International Inc.'s FY25 operating margin was 28.1%, against a 5-year range of 27.1% to 29.3%: the middle of its own range, neither a peak nor a low. The latest quarter was 31.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Mettler-Toledo International story? The main question: results are strong, and the P/E is higher than 82% of its own history. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Mettler-Toledo International a stock worth studying right now? What the numbers show: Mettler-Toledo International Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks

This is research, not advice. We’re not SEBI-registered.